Sunmax Biotechnology Statistics

Total Valuation

Sunmax Biotechnology has a market cap or net worth of TWD 14.87 billion. The enterprise value is 13.87 billion.

Market Cap	14.87B
Enterprise Value	13.87B

Important Dates

The next estimated earnings date is Monday, November 11, 2024.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	Jul 17, 2024

Share Statistics

Sunmax Biotechnology has 54.46 million shares outstanding. The number of shares has increased by 0.01% in one year.

Shares Outstanding	54.46M
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	-0.12%
Owned by Insiders (%)	8.64%
Owned by Institutions (%)	0.72%
Float	49.76M

Valuation Ratios

The trailing PE ratio is 20.92.

PE Ratio	20.92
Forward PE	n/a
PS Ratio	8.45
PB Ratio	12.48
P/FCF Ratio	26.66
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.50, with an EV/FCF ratio of 24.86.

EV / Earnings	19.48
EV / Sales	7.88
EV / EBITDA	13.50
EV / EBIT	14.77
EV / FCF	24.86

Financial Position

The company has a current ratio of 1.41, with a Debt / Equity ratio of 13.48.

Current Ratio	1.41
Quick Ratio	1.22
Debt / Equity	13.48
Debt / EBITDA	0.16
Debt / FCF	0.29
Interest Coverage	176.14

Financial Efficiency

Return on equity (ROE) is 62.86% and return on invested capital (ROIC) is 45.16%.

Return on Equity (ROE)	62.86%
Return on Assets (ROA)	25.00%
Return on Capital (ROIC)	45.16%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.75
Inventory Turnover	2.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +44.06% in the last 52 weeks. The beta is 0.32, so Sunmax Biotechnology's price volatility has been lower than the market average.

Beta (5Y)	0.32
52-Week Price Change	+44.06%
50-Day Moving Average	291.54
200-Day Moving Average	246.49
Relative Strength Index (RSI)	42.02
Average Volume (20 Days)	14,602

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sunmax Biotechnology had revenue of TWD 1.76 billion and earned 711.78 million in profits. Earnings per share was 13.05.

Revenue	1.76B
Gross Profit	1.46B
Operating Income	938.48M
Pretax Income	981.17M
Net Income	711.78M
EBITDA	994.03M
EBIT	938.48M
Earnings Per Share (EPS)	13.05

Full Income Statement

Balance Sheet

The company has 1.16 billion in cash and 160.57 million in debt, giving a net cash position of 1.00 billion or 18.42 per share.

Cash & Cash Equivalents	1.16B
Total Debt	160.57M
Net Cash	1.00B
Net Cash Per Share	18.42
Equity (Book Value)	1.19B
Book Value Per Share	21.88
Working Capital	393.54M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 646.17 million and capital expenditures -88.44 million, giving a free cash flow of 557.73 million.

Operating Cash Flow	646.17M
Capital Expenditures	-88.44M
Free Cash Flow	557.73M
FCF Per Share	10.24

Full Cash Flow Statement

Margins

Gross margin is 82.80%, with operating and profit margins of 53.33% and 40.45%.

Gross Margin	82.80%
Operating Margin	53.33%
Pretax Margin	55.76%
Profit Margin	40.45%
EBITDA Margin	56.49%
EBIT Margin	53.33%
FCF Margin	31.69%

Dividends & Yields

This stock pays an annual dividend of 11.00, which amounts to a dividend yield of 3.96%.

Dividend Per Share	11.00
Dividend Yield	3.96%
Dividend Growth (YoY)	15.79%
Years of Dividend Growth	5
Payout Ratio	72.69%
Buyback Yield	-0.01%
Shareholder Yield	3.95%
Earnings Yield	4.78%
FCF Yield	3.75%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a